| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
| US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236804 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
| US8193195 | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 3 months ago) | |
|
US7834020 (Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
|
US8193195 (Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
|
US8236804 (Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
|
US8673921 (Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(9 months ago) | |
Viibryd is owned by Allergan.
Viibryd contains Vilazodone Hydrochloride.
Viibryd has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Viibryd are:
- US8236804
- US8193195
- US7834020*PED
- US8193195*PED
- US8236804*PED
- US8673921*PED
- US7834020
- US8673921
Viibryd was authorised for market use on 21 January, 2011.
Viibryd is available in tablet;oral dosage forms.
Viibryd can be used as treatment of major depressive disorder (mdd).
The generics of Viibryd are possible to be released after 31 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jan 31, 2023 |
| Pediatric Exclusivity (PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
VIIBRYD family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic